Navin Robert Pinto, MD

Navin Robert Pinto, MD

Cancer and Blood Disorders Center, Neuroblastoma Program, Bone Tumors and Soft Tissue Tumors, I-131-MIBG Therapy, Apheresis, Solid Tumors Oncology

On staff since November 2015

Children's Title: Attending Physician, Cancer and Blood Disorders Center

Academic Title: Associate Professor of Pediatrics, University of Washington

"My goal to improve cure rates for childhood cancer using more targeted, less toxic therapies."

  • Navin Pinto, MD, is an attending physician at Seattle Children’s Hospital and an associate professor of pediatrics at the University of Washington School of Medicine. His clinical and research interests focus on cancer immunotherapy, specifically for children with solid tumors, and he is the medical lead of the Solid Tumor Immunotherapy Program at Seattle Children’s Therapeutics (https://www.seattlechildrens.org/research/therapeutics/).

    The goal of the Solid Tumor Immunotherapy Program is to improve outcomes of children with solid tumors through the use of adoptive immunotherapy, specifically through the use of chimeric antigen receptor T-cells (CAR T-cells).

    • Cherilyn Bothell 01.14.18

      With four cancer diagnoses in my immediate family we have encountered countless oncology and medical professionals. Dr. Pinto was our first oncologist and has remained my entire family's favorite medical professional. He is honest and forthcoming, yet sensitive and genuine. We never felt rushed and were always heard. Our son's treatment went exactly how he patiently explained it would. We are eternally grateful for Dr. Pinto.

    • Luciano SÃO PAULO/SP - BRAZIL 12.28.17

      We are having a great experience treating in Seattle with Dr. Pinto. He is a wonderful doctor, very atencious, and the most important he is fantastic human being.

    • Luciano SÃO PAULO/SP - BRAZIL 12.28.17

      We are having a great experience treating in Seattle with Dr. Pinto. He is a wonderful doctor, very atencious, and the most important he is fantastic human being.

  • Other Publications

    • Davis JL, Vargas SO, Rudzinski ER, López Marti JM, Janeway K, Forrest S, Winsnes K, Pinto N, Yang SE, VanSandt M, Boyd TK, Corless CL, Liu YJ, Surrey LF, Harris MH, Church A, Al-Ibraheemi A
      Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms.
      31994201 Histopathology, 2020 June : 76(7)1032-1041
    • Spencer K, Romberg E, Pinto N
      Extensive small bowel pneumatosis and ischemia during dinutuximab therapy for high-risk neuroblastoma.
      31925911 Pediatric blood & cancer, 2020 April : 67(4)e28147
    • Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
      Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
      31812554 The Lancet. Oncology, 2020 Jan. : 21(1)121-133
    • Pinto N, Naranjo A, Hibbitts E, Kreissman SG, Granger MM, Irwin MS, Bagatell R, London WB, Greengard EG, Park JR, DuBois SG
      Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).
      30947024 European journal of cancer (Oxford, England : 1990), 2019 May : 11266-79 PMCID:PMC6491235
    • Elzembely MM, Dahlberg AE, Pinto N, Leger KJ, Chow EJ, Park JR, Carpenter PA, Baker KS
      Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue.
      30151986 Pediatric blood & cancer, 2019 Jan. : 66(1)e27421
    • Tedesco KT, Sarthy J, Pinto N, Boos MD
      Acute enlargement of a vascular plaque and gait changes in a young girl.
      30487229 BMJ (Clinical research ed.), 2018 Nov. 28 : 363k4679
    • Elzembely MM, Park JR, Riad KF, Sayed HA, Pinto N, Carpenter PA, Baker KS, El-Haddad A
      Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources.
      30241255 Journal of global oncology, 2018 Sept. : 41-12 PMCID:PMC6223425
    • Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR
      A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
      29948021 Cancer chemotherapy and pharmacology, 2018 Aug. : 82(2)309-317 PMCID:PMC6739841
    • Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR
      Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
      29603591 Pediatric blood & cancer, 2018 July : 65(7)e27023 PMCID:PMC6040651
    • Ceppi F, Rivers J, Annesley C, Pinto N, Park JR, Lindgren C, Mgebroff S, Linn N, Delaney M, Gardner RA
      Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
      29536556 Transfusion, 2018 June : 58(6)1414-1420
    • Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, Pinto N, Kim ES, Schilsky RL
      Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
      30603737 JCO precision oncology, 2018 : 2018 PMCID:PMC6312096
    • Pinto N, Park JR, Murphy E, Yearley J, McClanahan T, Annamalai L, Hawkins DS, Rudzinski ER
      Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
      28488345 Pediatric blood & cancer, 2017 Nov. : 64(11)
    • Sokol E, Huang E, Pytel P, Cohn SL, Pinto N
      Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients.
      27663277 Pediatric blood & cancer, 2017 March : 64(3)
    • Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ
      Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.
      28033528 European journal of cancer (Oxford, England : 1990), 2017 Feb. : 72177-185 PMCID:PMC5258837
    • Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL
      Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.
      26864375 Pediatric blood & cancer, 2016 June : 63(6)1019-23 PMCID:PMC5109976
    • Pinto N, Hawkins DS
      Second Malignant Neoplasms in Rhabdomyosarcoma: Victims of Our Own Success or an Underlying Genetic Predisposition Syndrome?
      26505490 Pediatric blood & cancer, 2016 Feb. : 63(2)189-90
    • Darlington WS, Pinto N, Hecktman HM, Cohn SL, LaBelle JL
      Stem Cell Transplant-Associated Wernicke Encephalopathy in a Patient with High-Risk Neuroblastoma.
      26174546 Pediatric blood & cancer, 2015 Dec. : 62(12)2232-4
    • Darlington WS, Pinto N, Hecktman HM, Cohn SL, LaBelle JL
      Stem Cell Transplant-Associated Wernicke Encephalopathy in a Patient with High-Risk Neuroblastoma.
      26174546 Pediatric blood and cancer, 2015 Dec. : 62(12)2232-4
    • Pinto N, Hawkins DS
      Second Malignant Neoplasms in Rhabdomyosarcoma: Victims of Our Own Success or an Underlying Genetic Predisposition Syndrome?
      26505490 Pediatric blood and cancer, 2015 Oct. 27
    • Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL
      Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
      26304901 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015 Sept. 20 : 33(27)3008-17 PMCID:PMC4567703
    • Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL
      Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
      26304901 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015 Sept. 20 : 33(27)3008-17 PMCID:PMC4567703
    • Pinto N, Volchenboum SL, Skol AD, Rhodes L, Doan A, Fein-Levy C, Lipton JM, Cunningham JM, Onel K
      Establishing a translational genomics infrastructure in pediatric cancer: the GREAT KIDS experience.
      29771652 Personalized medicine, 2015 June : 12(3)221-229
    • Applebaum MA, Henderson TO, Lee SM, Pinto N, Volchenboum SL, Cohn SL
      Second malignancies in patients with neuroblastoma: the effects of risk-based therapy.
      25251613 Pediatric blood and cancer, 2015 Jan. : 62(1)128-33 PMCID:PMC4237647
    • Madian AG, Panigrahi A, Perera MA, Pinto N
      Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution.
      25472557 BMC pharmacology & toxicology, 2014 Dec. 3 : 1569 PMCID:PMC4287354
    • Pinto N, Cipkala DA, Ladd PE, Pu Y, Cohn SL
      Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation.
      24293072 Pediatric blood & cancer, 2014 June : 61(6)1104-6
    • Staley S, Hageman JR, Pinto N, Khan N
      An arresting sickle cell disease complication.
      24168124 Pediatric annals, 2013 Nov. : 42(11)448-51
    • Gamazon ER, Pinto N, Konkashbaev A, Im HK, Diskin SJ, London WB, Maris JM, Dolan ME, Cox NJ, Cohn SL
      Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival.
      23243203 Journal of the National Cancer Institute, 2013 Feb. 20 : 105(4)302-9 PMCID:PMC3691940
    • Pinto N, Cohn SL, Dolan ME
      Using germline genomics to individualize pediatric cancer treatments.
      22589487 Clinical cancer research : an official journal of the American Association for Cancer Research, 2012 May 15 : 18(10)2791-800 PMCID:PMC3354919
    • Pinto N, Dolan ME
      Clinically relevant genetic variations in drug metabolizing enzymes.
      21453273 Current drug metabolism, 2011 June : 12(5)487-97 PMCID:PMC3110519

  • Presentations Title Event Location Date
    Invited Speaker, Pediatrics Grand Rounds University of New Mexico Comprehensive Cancer Center Albuquerque, NM 2018
    Visiting Professor, Annual Fellow’s Lecture University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics Chicago, IL 2018
    High-Risk Neuroblastoma, An Update Pediatric Oncology Grand Rounds, Tata Memorial Hospital Mumbai, India 2017
    Oral Abstract: Pharmacogenetics of Treatment Response in High-Risk Neuroblastoma: A Children’s Oncology Group Study Advances in Neuroblastoma Research Cairns, Australia 2016
    High-Risk Neuroblastoma Seattle Children's Hospital, Nursing Education Day Seattle, WA 2016
    Integrating Cell-Based and Clinical Genome-Wide Studies to Identify Drug-Specific Mechanisms of Treatment Failure in Neuroblastoma Patients. Grand Rounds, University of Chicago, Department of Pediatrics Chicago, IL 2013
    Relationship of divergent ancestral genetic variation on chromosome 6p22 and racial disparities in survival in neuroblastoma Advances in Neuroblastoma Research Toronto, ON, Canada 2012
    Relationship of divergent ancestral genetic variation on chromosome 6p22 and racial disparities in survival in neuroblastoma American Society of Clinical Oncology Chicago, IL 2012
    A Foot in Both Worlds, Caring for Children with Life-Threatening Illness Pediatric Palliative Care: State of the Practice Barrington, IL 2011
    Survival Variability by Race and Ethnicity in Neuroblastoma: A Children's Oncology Group Study Advances in Neuroblastoma Research Stockholm, Sweden 2010
  • Grant Title Grantor Amount Award Date
    L1CAM Chimeric Antigen Receptor T Cell Therapy for Small Cell Neuroendocrine Prostate Cancer Prostate Cancer Foundation $62,869 Oct. 11, 2019 - Oct. 10, 2021
    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma Merck Sharp & Dohme Corp. $280,000 Dec. 26, 2016 - July 31, 2023
    Genomics of Treatment Failure in Neuroblastoma St. Baldrick's Foundation $445,000 July 1, 2012 - June 30, 2016

Overview

Board Certification(s)

Pediatrics
Pediatric Hematology-Oncology

Medical/Professional School

Saint Louis University School of Medicine, St Louis

Residency

Pediatrics, University of Chicago, Chicago

Fellowship

Pediatric Hematology Oncology, University of Chicago, Chicago

Clinical Interests

Neuroblastoma, Solid Tumors, Cancer Immunotherapy

 

Research Description

I am a pediatric oncologist and clinical researcher with a focus on clinical trial design and implementation to study new therapies for children with cancer. My specific focus is on the use of cancer immunotherapies like CAR T cells to treat relapsed and refractory childhood solid tumors. 

Research Focus Area

Cancer biology, Refractory and recurrent cancer, Sarcomas, Thyroid Cancer